Moreover, the BELLE-3 phase III trial is investigating the efficacy of buparlisib plus fulvestrant in postmenopausal patients with HR+/HER2− advanced BC previously treated with an aromatase inhibitor and refractory to mTOR inhibitor-based therapy. Here, CYP19A1 is linked to breast cancer.